Topical loteprednol etabonate 0.5% for treatment of vernal keratoconjunctivitis: Efficacy and safety

Japanese Journal of Ophthalmology

Volumn 56, Issue 4, 2012, Pages 312-318

  Öner, Veysi ^a   Türkcü, Fatih Mehmet ^a   Taş, Mehmet ^a   Alakuş, Mehmet Fuat ^a   Işcan, Yalçin ^a  

^a Batman State Hospital   (Turkey)

Author keywords

Fluorometholone; Loteprednol etabonate; Prednisolone; Vernal keratoconjunctivitis

Indexed keywords

FLUOROMETHOLONE ACETATE; LOTEPREDNOL ETABONATE; PREDNISOLONE ACETATE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CHEMOSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PANNUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VERNAL CONJUNCTIVITIS;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ALLERGENS; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; CONJUNCTIVITIS, ALLERGIC; FEMALE; FLUOROMETHOLONE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; PREDNISOLONE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 84863880005     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-012-0152-5     Document Type: Article

References (37)

1. Ehlers WH, Donshik PC. Allergic ocular disorders: a spectrum of diseases. CLAO J. 1992;18:117-24.
2. Abelson MB, George MA, Garofalo C. Differential diagnosis of ocular allergic disorders. Ann Allergy. 1993;70:95-109. (Pubitemid 23062803)
3. Shoji J, Inada N, Sawa M. Antibody array-generated cytokine profiles of tears of patients with vernal keratoconjunctivitis or giant papillary conjunctivitis. Jpn J Ophthalmol. 2006;50:195-204. (Pubitemid 43881992)
4. Kosrirukvongs P, Visitsunthorn N, Vichyanond P, Bunnag C. Allergic conjunctivitis. Asian Pac J Allergy Immunol. 2001;19:237-44. (Pubitemid 34436217)
5. Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O, et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology. 2000;107:1157-63.
6. Leonardi A, Secchi AG. Vernal keratoconjunctivitis. Int Ophthalmol Clin. 2003;43:41-58. (Pubitemid 36150939)
7. Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res. 2002;21:319-39. (Pubitemid 34614554)
8. Verin PH, Dicker ID, Mortemousque B. Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis. Clin Exp Allergy. 1999;29:529-36. (Pubitemid 29179823)
9. BenEzra D. Current practice: diagnosis and treatment in primary healthcare. Allergy. 1995;50:30-3.
10. Trocme SD, Raizman MB, Bartley GB. Medical therapy for ocular allergy. Mayo Clin Proc. 1995;67:6-9.
11. Jerndal T, Munkby M. Corticosteroid response in dominant congenital glaucoma. Acta Ophthalmol (Copenh). 1978;56:373-83. (Pubitemid 8355396)
12. Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444-57. (Pubitemid 39208573)
13. Dell SJ, Lowry GM, Northcutt JA, Howes J, Novack GD, Hart K. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis. J Allergy Clin Immunol. 1998;102:251-5.
14. Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens. 2004;30:10-3. (Pubitemid 43196972)
15. Stewart R, Horwitz B, Howes J, Novack GD, Hart K. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1. J Cataract Refract Surg. 1998;24:1480-9. (Pubitemid 28509816)
16. Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol. 1997;123:455-64. (Pubitemid 27171850)
17. Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol. 1999;127:537-44.
18. Kheirkhah A, Zavareh MK, Farzbod F, Mahbod M, Behrouz MJ. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond). 2011;25:872-80.
19. Uchio E, Itoh Y, Kadonosono K. Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis. Ophthalmologica. 2007;221:153-8. (Pubitemid 46631915)
20. Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 2005;7:820-33.
21. Howes J, Novack GD. Failure to detect systemic levels, and effects of loteprednol etabonate and its metabolite, pj-91, following chronic ocular administration. J Ocul Pharmacol Ther. 1998;14:153-8. (Pubitemid 28178212)
22. Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma. Prog Retin Eye Res. 1999;18:629-67. (Pubitemid 29299153)
23. Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol. 1993;9:157-65. (Pubitemid 23187584)
24. Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma. 1998;7:266-9. (Pubitemid 29149820)
25. Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea. 2008;27:50-5.
26. White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis. Curr Med Res Opin. 2008;24:287-96. (Pubitemid 351181204)
27. Bucala R, Gallati M, Manabe S, Cotlier E, Cerami A. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. Exp Eye Res. 1985;40:853-63. (Pubitemid 16162048)
28. Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res. 1991;10:933-7.
29. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008;92:455-9. (Pubitemid 351497967)
30. Bilgihan K, Gurelik G, Akata F, Hasanreisoglu B. Fluorometholone induced cataract after photorefractive keratectomy. Ophthalmologica. 1997;211:394-6. (Pubitemid 27431902)
31. Costagliola C, Cati-Giovannelli B, Priccirrillo A, Delfino M. Cataracts associated with long-term topical steroids. Br J Dermatol. 1989;120:472-3. (Pubitemid 19086640)
32. Keklikci U, Soker SI, Sakalar YB, Unlu K, Ozekinci S, Tunik S. Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. Jpn J Ophthalmol. 2008;52:357-62.
33. Lambiase A, Leonardi A, Sacchetti M, Deligianni V, Sposato S, Bonini S. Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. J Allergy Clin Immunol. 2011;128:896-7.
34. Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, et al. Effi cacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2002;89:298-303.
35. Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P. Vernal keratoconjunctivitis: result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol. 2004;113:355-8. (Pubitemid 38210564)
36. Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol. 1987;139:1797-803. (Pubitemid 17141605)
37. Friedlaender MH. Ocular allergy. Curr Opin Allergy Clin Immunol. 2011;11:477-82